Drug Trial Radar · NCT06523153
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
May 2025
Study completion May 2025
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants
Conditions
- COVID-19
Interventions
VYD2311Biological
Monoclonal antibody
PlaceboOther
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs (including AEs and SAEs)Time frame: Through Month-6 visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Invivyd Investigative Site
Joondalup, WA 6027, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.